1. Home
  2. NCRA vs REVB Comparison

NCRA vs REVB Comparison

Compare NCRA & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

N/A

Current Price

$0.35

Market Cap

5.6M

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.27

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
REVB
Founded
2002
2020
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
REVB
Price
$0.35
$1.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
30.5K
155.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.47
52 Week High
$2.40
$3.73

Technical Indicators

Market Signals
Indicator
NCRA
REVB
Relative Strength Index (RSI) 29.23 49.05
Support Level N/A $0.77
Resistance Level $0.58 $1.38
Average True Range (ATR) 0.06 0.09
MACD 0.01 -0.03
Stochastic Oscillator 20.78 39.33

Price Performance

Historical Comparison
NCRA
REVB

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: